The fourth-generation targeted drugs include Vimofenib, Dabrafenib, Trametinib, Cobitinib, such as Imatinib as well as BLU-945. 1. Vemofenib and Darafenib belong to BRAF inhibitors, which can play a role in inhibiting the cellular MEK/ERK transduction signaling pathway. 2. Trametinib and cobimetinib are MEK inhibitors, which can provide targeted treatment for patients with two types of mutations (BRAFV600E and V600K). 3. Imatinib belongs to C-KIT inhibitors, which can provide targeted treatment for patients with diseases caused by C-KIT gene mutations. 4. BLU-945 is a selective EGFR inhibitor that can target EGFR, T790M and C797S mutations. Please follow your doctor’s instructions and do not self-medicate.